Form 10-Q uniQure N.V. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
RBC Capital on uniQure BV (QURE): 'Brain Safety Signal Unfortunate, But Stock Reaction Overdone'
August 8, 2022 12:59 PM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $53.00 price target on uniQure BV (NASDAQ: QURE)
The analyst comments "Huntington's brain safety signal is unfortunate as it will delay the program, formal FDA clinical hold is possible and one patient has... More
Cowen on uniQure BV (QURE): 'We are hopeful the risk is manageable'
August 8, 2022 12:59 PM EDTCowen analyst Joseph Thome reiterated an Outperform rating on uniQure BV (NASDAQ: QURE).
The analyst comments "While the news is unfortunate and warrants additional investigation, we note that the U.S. data update remains on track for Q2:23 and a total of... More
Goldman Sachs Reiterates Buy Rating on uniQure BV (QURE)
August 8, 2022 12:57 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $51.00 price target on uniQure BV (NASDAQ: QURE).
The analyst comments "QURE released 2Q EPS and announced the postponement of procedures in the higher-dose cohort (6x1013vg) of the Ph1/2 US and Ph1b/2 EU studies of gene therapy AMT-130 in Huntingtons disease due to suspected unexpected... More
Credit Suisse Reiterates Outperform Rating on uniQure BV (QURE), 'Catalysts On-Track'
August 8, 2022 12:54 PM EDTCredit Suisse analyst Judah C. Frommer reiterated an Outperform rating and $51.00 price target on uniQure BV (NASDAQ: QURE)
The analyst comments "With 2Q22 earnings QURE disclosed pausing of enrollment in the high-dose cohort of its Ph1/2 AMT-130 (Huntingtons GT) trial following DSMB recommendation tied to 3 suspected unexpected severe adverse... More
